QYNAPSE is already marketing its first QyScore® medical device in clinical centers L’Europe and United States. Its platform is also used in clinical trials involving dozens of centers around the world. Collaboration with TPMD will allow QYNAPSE to extend the applications of its QyScore® software for other brain diseases such as stroke, epilepsy, autism, schizophrenia and head trauma – and also to develop new software to predict the clinical progression of individual patients and optimize recruitment into them. clinical tests.
The acquisition of TPMD by QYNAPSE covers 15 patents, including 9 issued in United States and Canada, grouped into nine families of technological assets. The founders of TPMD will join the scientific board of QYNAPSE, paving the way for a long-term collaboration.
According to Prof. Louis Collins: « QYNAPSE is a very promising partner for TPMD and both McGill and Laval universities, which will allow us to accelerate regulatory approval and commercialization of the technologies we have developed in recent years“. Professor Duchesne adds, “Indeed, with QYNAPSE we will have access to a partner already well established in the medical field. We look forward to providing clinicians with the tools they need to improve diagnostic accuracy, aid prognosis, and guide the treatment of conditions such as dementia and cerebrovascular disease.. »
« We are delighted to partner with two of the world’s leading experts in brain imaging and to expand our scientific and clinical collaborations with two major centers of excellence in this field. ” said Olivier Courrèges, CEO of QYNAPSE. ” This collaboration will create a unique technological framework, strengthening our ability to deploy powerful tools to address two major challenges: the performance of clinical trials and the personalized management of brain diseases, which affect more than one in six people worldwide. »
Once finalized, TPMD will be integrated into QYNAPSE CANADA Inc. and TPMD’s scientific and commercial partnership contracts will be managed by this new entity.
Founded in 2015, QYNAPSE is a French medical technology company, a spin-off of the CATI consortium of neuroimaging research laboratories. The company develops and markets solutions using the potential of quantitative imaging and artificial intelligence to optimize the diagnosis, prognosis and follow-up of patients with neurological diseases.
QYNAPSE is headquartered at Paris, France) et en Boston (United States).
About TRUE POSITIVE MEDICAL DEVICES (LDCT)
Founded in 2011, TRUE POSITIVE MEDICAL DEVICE Inc. is a spin-off of the work of Prof. Simon duchesne at CERVO Brain Research Center and at the University Laval and Prof. Louis Collins at the Montreal Neurological Institute and mcgill university. The company designs, validates and operates a brain image processing platform to aid in the diagnosis and prognosis of neurological and psychiatric diseases.
TPMD is based on Montréal and Quebec city (QC, Canada).
Logo – https://mma.prnewswire.com/media/1311169/Qynapse_Logo.jpg
Photo – https://mma.prnewswire.com/media/1311170/QyScore_application.jpg
Ysé Sallé de Chou
For more information: [email protected] – +33 (0) 18.104.22.168.43